Baxalta submits sBLAs to FDA for approval of ADYNOVATE
Baxalta Inc., a worldwide leader in pharmaceuticals committed to developing therapies to combat orphan diseases, has announced the submission of supplemental Biologics License Applications (sBLAs) for the approval of ADYNOVATE by the U.S. Food and Drug Administration (FDA). Read More »